NEW YORK (GenomeWeb News) – Biosearch Technologies today said that it has licensed to Seegene patents covering its BHQ, CAL Fluor, and Quasar technologies.
Under terms of the deal, Novato, Calif.-based Biosearch also will manufacture both research and IVD-grade oligonucleotides for Seegene, a Korean firm that makes PCR-based molecular diagnostic products. Financial and other terms of the agreement were not disclosed.
"Seegene's multiplex PCR technology, combined with Biosearch's BHQ, CAL Fluor, Quasar IP and oligo manufacturing expertise are a powerful and innovative solution in multiplex molecular diagnostics on real time PCR platforms," Marc Beal, director of corporate development at Biosearch, said in a statement.